TEAD-Inhibiting Therapeutic Compounds for Hippo Pathway Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for cancer and other diseases often involve the development of resistance to the Hippo pathway, which is a regulator of animal development, organ size control, and stem cell regulation, and its deregulation is implicated in a wide range of malignancies, including lung, breast, head and neck, colon, ovarian, liver, brain, and prostate cancers, mesotheliomas, sarcomas, and leukemia. The Hippo pathway's interaction with other signaling pathways like Wnt, Notch, and Hedgehog influences various biological events and could be involved in many human diseases beyond cancer.
Innovation Solution
Development of compounds that inhibit TEAD, a key component of the Hippo pathway, to modulate its activity and potentially treat or prevent cancers by targeting the Hippo pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for cancer, then initial therapeutic effect is achieved, but resistance to the Hippo pathway develops over time
Solution Approach 1:
The patent inverts the conventional approach by directly targeting TEAD transcription factors instead of targeting YAP/TAZ downstream effectors. This inverse strategy prevents resistance development by attacking the pathway at a different, upstream node that is less prone to adaptive resistance mechanisms.
Solution Approach 2:
The patent introduces compounds that act as intermediaries to block the interaction between TEAD transcription factors and their DNA binding sites or co-activators. These compounds serve as mediators that prevent the formation of active transcriptional complexes without directly interfering with YAP/TAZ protein function, thereby maintaining therapeutic efficacy while avoiding resistance.
2Reliability
If TEAD inhibition compounds are developed, then Hippo pathway activity is modulated to treat cancer, but the complexity of the treatment approach increases
Solution Approach 1:
The patent extracts and isolates the specific TEAD transcription factor binding site interactions as the primary target, separating this function from the complex downstream Hippo pathway signaling cascade. By focusing on this single, well-defined molecular interaction, the treatment approach becomes more targeted and less complex while maintaining high therapeutic efficacy.
Solution Approach 2:
The patent develops compounds that can universally inhibit multiple TEAD family members (TEAD1-4) with a single molecular structure. This multi-functional approach allows one compound to address the entire TEAD family's oncogenic activity, simplifying the treatment strategy compared to developing separate inhibitors for each TEAD isoform.
Data Source
AI summary
The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.